PMID- 33185693
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20210412
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 40
IP  - 11
DP  - 2020 Nov 27
TI  - MR1-restricted T cells: the new dawn of cancer immunotherapy.
LID - 10.1042/BSR20202962 [doi]
LID - BSR20202962
AB  - Cancer immunotherapy has recently undergone rapid development into a validated 
      therapy for clinical use. The adoptive transfer of engineered autologous T cells, 
      such as chimeric antigen receptor (CAR) T cells, has been remarkably successful 
      in patients with leukemia and lymphoma with cluster of differentiation (CD)19 
      expression. Because of the higher number of antigen choices and reduced incidence 
      of cytokine release syndrome (CRS) than CAR-T cells, T cell receptor (TCR)-T 
      cells are also considered a promising immunotherapy. More therapeutic targets for 
      other cancers need to be explored due to the human leukocyte antigen 
      (HLA)-restricted recognition of TCR-T. Major histocompatibility complex (MHC), 
      class I-related (MR1)-restricted T cells can recognize metabolites presented by 
      MR1 in the context of host cells infected with pathogens. MR1 is expressed by all 
      types of human cells. Recent studies have shown that one clone of a 
      MR1-restricted T (MR1-T) cell can recognize many types of cancer cells without 
      HLA-restriction. These studies provide additional information on MR1-T cells for 
      cancer immunotherapy. This review describes the complexity of MR1-T cell TCR in 
      diseases and the future of cancer immunotherapy.
CI  - (c) 2020 The Author(s).
FAU - Wang, Zhiding
AU  - Wang Z
AD  - Department of Hematology and Oncology, International Cancer Center, Shenzhen 
      University General Hospital, Shenzhen University Health Science Center, Shenzhen 
      518000, China.
AD  - Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 
      100853, China.
FAU - Wang, Mengzhen
AU  - Wang M
AD  - Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 
      100853, China.
FAU - Chen, Jinghong
AU  - Chen J
AD  - Department of Hematology and Oncology, International Cancer Center, Shenzhen 
      University General Hospital, Shenzhen University Health Science Center, Shenzhen 
      518000, China.
FAU - Zhang, Linlin
AU  - Zhang L
AD  - Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 
      100853, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Hematology and Oncology, International Cancer Center, Shenzhen 
      University General Hospital, Shenzhen University Health Science Center, Shenzhen 
      518000, China.
FAU - Yu, Li
AU  - Yu L
AD  - Department of Hematology and Oncology, International Cancer Center, Shenzhen 
      University General Hospital, Shenzhen University Health Science Center, Shenzhen 
      518000, China.
AD  - Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing 
      100853, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (MR1 protein, human)
RN  - 0 (Minor Histocompatibility Antigens)
SB  - IM
MH  - Animals
MH  - Histocompatibility Antigens Class I/genetics/*immunology/metabolism
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Lymphocytes, Tumor-Infiltrating/*immunology/metabolism
MH  - Minor Histocompatibility Antigens/genetics/*immunology/metabolism
MH  - Mucosal-Associated Invariant T Cells/*immunology/metabolism
MH  - Neoplasms/genetics/immunology/metabolism/*therapy
MH  - Phenotype
MH  - Prognosis
MH  - T-Lymphocytes/immunology/metabolism/*transplantation
PMC - PMC7670570
OTO - NOTNLM
OT  - Cancer
OT  - Immunotherapy
OT  - MAIT
OT  - MR1
OT  - MR1-restricted T cell
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2020/11/14 06:00
MHDA- 2021/04/13 06:00
PMCR- 2020/11/13
CRDT- 2020/11/13 12:10
PHST- 2020/08/26 00:00 [received]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/13 12:10 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
PHST- 2020/11/13 00:00 [pmc-release]
AID - 226783 [pii]
AID - BSR20202962 [pii]
AID - 10.1042/BSR20202962 [doi]
PST - ppublish
SO  - Biosci Rep. 2020 Nov 27;40(11):BSR20202962. doi: 10.1042/BSR20202962.